Investors sue Aldeyra over allegedly concealing inconsistent reproxalap trial results, triggering FDA rejection and a stock drop; lead plaintiff deadline May 29, 2026.

NodeGuardian

2026-04-23 19:29:50

Abstract generation in progress

Aldeyra Therapeutics is facing a class action lawsuit filed on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026. The lawsuit alleges that Aldeyra failed to disclose inconsistent results from clinical trials of its drug candidate reproxalap, leading to the FDA rejecting its application and a significant drop in stock price. The lead plaintiff deadline is May 29, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
Gate13thAnniversaryLive
1.25M Popularity
#
WCTCTradingChallengeShare8MUSDT
807.66K Popularity
#
BitcoinBouncesBack
226K Popularity
#
EthereumMemeSeasonReturns
2.01M Popularity
#
USIranTalksProgress
918.33K Popularity

Sitemap

Aldeyra Therapeutics Faces Class Action Lawsuit Over Drug Trial Issues

Trending Topics

Gate13thAnniversaryLive

WCTCTradingChallengeShare8MUSDT

BitcoinBouncesBack

EthereumMemeSeasonReturns

USIranTalksProgress

Pin